Research tripeptide · U.S.-focused educational profile
alpha-MSH(11-13), KPV tripeptide, Lys-Pro-Val
The three-amino-acid peptide lysine-proline-valine, studied in cell and animal inflammation models. It is not an FDA-approved drug.[1]
How to use this page: match the exact product, form, route, population, and use before applying any evidence. This profile does not assess individual suitability.
This page identifies the named substance and the published context around it. A brand name, alias, salt, fragment, or cosmetic ingredient may not represent the same evidence or product.
Evidence can change with a product's chemical form, formulation, route, ingredients, and manufacturing. Similar names do not establish that two products are equivalent.
These are published research or product contexts. They are not indications selected for an individual and do not say that a compound is suitable for a particular person.
A formulation is the specific product form, such as a tablet, cream, or injection. A route describes how it reaches the body. The entries below describe the cited product or research context; they are not instructions for use.
[1]No FDA-approved route or human exposure route was identified. Proposed compounded routes are not instructions or evidence of safety.
[1]Human evidence can mean a controlled clinical study, an observational study, a safety or exposure report, or evidence from a particular finished formulation. Those are different kinds of information.
Mostly laboratory or animal evidence. The evidence is mainly from cells, tissues, or animals. Any human information is limited or indirect and does not establish a clinical outcome.
Recovery and inflammatory research
FDA found no human exposure data for KPV by any route. Consequently, effectiveness and clinical safety have not been established.
Translation from cell and mouse models, human pharmacology, exposure, long-term effects, formulation identity, and safety are unresolved. The free base and acetate salt should not be treated as interchangeable.
Open source [1]More human evidence does not automatically mean better results for a different product, route, population, or purpose. Limited or missing evidence does not prove that a compound has no biological activity; it means the relevant clinical question has not been established by the published material reviewed here.
Preclinical means research in cells, tissues, or animals rather than in people. It can help researchers form a hypothesis, but it cannot establish a human benefit or a complete human safety profile.
Published work includes human cell-line experiments and mouse colitis models reporting anti-inflammatory and antimicrobial signals. These findings do not demonstrate a benefit or safety profile in people.[2]
Preclinical findings do not establish outcomes in people.
Risk information may describe the compound, a finished product, a route, a population, or product-quality concerns. The cited material does not replace a current product label or an individual professional assessment.
FDA identified absent clinical and adequate nonclinical safety data, along with possible immunogenicity, aggregation, impurity, and product-characterization concerns. Unapproved products add quality and sterility risks.
Research or cosmetic products may add identity, strength, purity, sterility, contamination, or formulation concerns. This is separate from the evidence about the compound itself.Open source [1]Translation from cell and mouse models, human pharmacology, exposure, long-term effects, formulation identity, and safety are unresolved. The free base and acetate salt should not be treated as interchangeable.
Human outcomes, long-term safety, formulation identity, and product consistency remain limited or unresolved in the cited material.Open source [1]Common effects, important warnings, product-quality concerns, and evidence gaps are not the same thing. A risk mentioned in one product label may not apply to every formulation, and an uncertainty is not proof of either safety or harm.
This section is about the United States only. Status applies to a product, formulation, route, population, and use—not to a name in the abstract. A status shown here is not a recommendation or a statement about another country.
No FDA-approved medicine was identified for this defined material. Research findings and products sold outside reviewed trials should not be treated as approval.
KPV is not an FDA-approved drug. In a May 2026 staff briefing prepared for the July 23-24 advisory-committee meeting, FDA said the evaluation criteria weighed against 503A Bulks List inclusion; FDA stated that no final determination would be issued until the advisory process and reviews were complete.
Specific product form or route is not separately published in this status record.
Open source contextThe date above is the date attached to the published status record or source context. It is not necessarily the original approval date.
These prompts help organise a conversation with a qualified professional. They do not create a treatment recommendation, dose, or protocol.
PeptideGrid review date: Jul 22, 2026. Sources support the specific sections that cite them. Publication does not imply endorsement, equivalence, or individual suitability.
FDA staff briefing for KPV-related substances
U.S. Food and Drug Administration. FDA Evaluation of KPV-Related Bulk Drug Substances (KPV (Free Base) and KPV Acetate). Pharmacy Compounding Advisory Committee briefing document. 2026.
U.S. Food and Drug Administration · Published May 12, 2026 · Accessed Jul 22, 2026 · Regulatory source
Open sourceKPV in cell and mouse colitis models
Dalmasso G, et al. The anti-inflammatory peptide KPV has anti-inflammatory and antimicrobial properties. Gastroenterology. 2008;134(1):166-178.
PubMed-indexed primary study · Published Jan 1, 2008 · Accessed Jul 22, 2026 · Preclinical study
Open sourcePeptideGrid separates identity, human evidence, laboratory and animal findings, risks, uncertainty, and product-specific U.S. status. Missing information stays marked as unpublished instead of being inferred. The Library is an educational source-and-structure resource, not a clinician review or a suitability assessment.
